• Variables included in both data sets were time to PFS, its corresponding censoring indicator, and the following patient characteristic variables of interest: age, sex, disease stage, laboratory test positivity, and brain metastases history.
Statistical Methods
• Descriptive statistics of patient characteristics were generated for Trial 1 and compared to the APD from Trial 2 to assess differences between trials.
• Cox regression was employed in Trial 1 to compute the unadjusted HR and 95% CLs of treatment A versus placebo. This estimate was then combined with the HR of treatment B versus placebo available in Trial 2 to compute a naïve HR of treatment A versus treatment B (serving as a reference point for the unadjusted treatment comparison).
• To serve as a fully adjusted treatment comparison reference point, the simulated data from Trial 2 were used as IPD, rather than APD, and combined with the IPD from Trial 1. A "head-tohead" propensity-score adjusted HR of treatment A versus treatment B was generated.
Covariate Centering with Multivariable Modeling (CCMM)
• Each patient characteristic variable (covariate) in Trial 1 was "centered" on Trial 2. Centering occurred by subtracting the mean value of each covariate reported in the APD of Trial 2 from the corresponding value for each patient in Trial 1.
• Cox regression on PFS time was performed on Trial 1 data with the following explanatory variables: treatment group, each centered covariate, and interactions between treatment group and each centered covariate.
• The adjusted HR of treatment A versus placebo was estimated by assigning a value of 0 to each centered covariate. Anchored indirect comparison (AIC) was performed to estimate the adjusted HR of treatment A versus treatment B.
Matching-Adjusted Indirect Comparison (MAIC)
• Methods described by Signorovitch 1, 4 were applied to assign a weight to each patient in Trial 1 such that patient characteristics were balanced with those reported in Trial 2.
• Postmatched weighted patient characteristics in Trial 1 were compared with those from the APD reported in Trial 2 to assess the performance of the matching procedure.
• Weighted Cox regression on PFS time with treatment as the sole predictor variable was performed to determine the adjusted HR of treatment A versus placebo. AIC was performed to estimate the adjusted HR of treatment A versus treatment B.
Simulated Treatment Comparison (STC)
• A Cox regression on PFS time was performed on Trial 1 data to generate a predictive model for the outcome as a function of the following characteristics: treatment group, age, sex, disease stage, laboratory test positivity, brain metastases history, and the interaction between treatment group and laboratory test positivity.
• To avoid nonlinearity bias as described in Ishak et al., 2 a patient profile data set was simulated based on the mean values of patient characteristics reported in the APD for Trial 2 under the multivariate-normal distribution.
• The coefficients of the predictive model were applied to each simulated patient profile to compute individual log hazards and the adjusted HR of treatment A versus placebo. AIC was performed to estimate the adjusted HR of treatment A versus treatment B. • In special cases, however, when IPD are available for one trial and APD are available for another trial, alternative methods can provide an additional level of control through the adjustment of patient characteristics between trials.
1,2
• Methods that combine IPD and APD to make indirect treatment comparisons include covariate centering with multivariable modeling (CCMM), matching-adjusted indirect comparison (MAIC), and simulated treatment comparison (STC).
OBJECTIVE
• To use simulated data sets for two oncology clinical trials to compare the CCMM, MAIC, and STC methods in the estimation of a progression-free survival (PFS) HR in the scenario where IPD are available for one trial and APD are available for another trial.
METHODS

Data
• Patient-level data sets were generated to simulate two oncology clinical trials, each with 1,000 patients (500 in each arm) who met identical assumed entry criteria ( Figure 1 
RESULTS
• The age and sex distribution of patients was similar between trials. Patients in Trial 1 were less likely to have late-stage disease and more likely to have positive laboratory tests and a history of brain metastases than patients in Trial 2 (Table 1 ).
• • The adjusted HR derived from the CCMM method of treatment A versus placebo was 0.28 (95% CL, 0.22, 0.35) ( Table 2 ).
• After applying MAIC, patient characteristics from Trial 1 and Trial 2 were adequately balanced ( Table 3 ). The adjusted HR of treatment A to placebo patients was 0.31 (95% CL, 0.26, 0.37).
• Upon implementation of the STC method, the adjusted HR of treatment A versus placebo was 0.31 (95% CL, 0.29, 0.33) ( Table 4 ).
• The results of the "head-to-head" propensity-score analysis yielded a fully adjusted reference point HR of 0.79 (95% CL, 0.63, 0.99) for treatment A versus treatment B.
• For the CCMM, MAIC, and STC methods, the adjusted treatment A versus treatment B HR values are presented in Figure 2 along with the naïve and fully adjusted reference points. 
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